Brazil’s New Patent Agreement Is “Real and Concrete Threat” To IP
Executive Summary
An agreement between Brazil’s medicines regulator, ANVISA, and the National Institute of Industrial Property, INPI, aimed at clearly defining their respective roles in the patent application process could pose a threat to the patent system, say IPR experts.
You may also be interested in...
Brazil's Product Licensing Restrictions Eventually May Get Easier
Brazilian drug regulator Anvisa has made some changes over the years, but still restricts companies with approved Rx products from licensing them to another company.
Brazil Patent Agreement Hopes To Increase Flow Of Generics To Market
Joint ordinance signed by Anvisa and INPI hopes to resolve a 16-year impasse between the two agencies and bring predictability to patent application process; Anvisa will be relegated to analyzing public health matters, while INPI will make final patentability determinations.
Brazil Prepares To Make Its Own Sovaldi As Regulator Opposes Patent Application
Brazil could soon be manufacturing its own generic version of Gilead’s Sovaldi if opposition to the company’s patent application is upheld by the patent office.